In 2019, the team of specially appointed associate professor Satoshi Yamazaki (currently a professor at the University of Tsukuba) and specially appointed professor Hiromitsu Nakauchi (also a professor at Stanford University) at The Institute of Medical Science, The University of Tokyo, succeeded in developing in-vitro propagation technology for use with mouse HSCs^*1.
In addition to being able to expand HSCs in large quantities in-vitro, they also discovered a growth medium that does not use biological substances, such as serum albumin or cytokines, which restricts variations in the media components to an absolute minimum, paving the way for the stable expansion of high-quality, large volume and inexpensive HSCs.
Subsequently, they further expanded their results and succeeded in developing a growth medium customized for human HSCs ^*2,3,4. As a result, they have reached the stage where these technologies can be put into practical use as products for regenerative medicine, etc., and Celaid Therapeutics has inherited these research results and is working towards concrete commercialization.

• *1 Adam et. al., Long -term ex vivo hematopoietic-stem-cell expansion allows nonconditioned transplantation. Nature. 2019 Jul.
• *2 Sakurai et. al., In vivo expansion of functional human hematopoietic stem progenitor cells by butyzamide. Int J Hematol. 2020 Mar.
• *3 WO 2021/049617
• *4 WO 2021/149799